THANK YOU BROTHER, RICIN
A questionable green light from the U.S. Food and Drug Administration (FDA). Medical experts left confused and concerned.
This is the story surrounding brexpiprazole, branded as Rexulti: the first antipsychotic approved to treat agitation in Alzheimer’s patients despite alarmingly high death rates and poor results in clinical trials.
Patients prescribed brexpiprazole faced a fourfold increased risk of dying compared to people who didn’t take the drug, according to an investigation published in the British Medical Journal (BMJ).
For medical professionals, the FDA’s move raises troubling questions about efficacy, safety, and regulatory diligence.
Please think about donating below.